Apr 16, 2025
Apr 16, 2025
chat
CDC ACIP Meeting: RSV Vaccines, Public Comment, Voting + More
Agenda:
Welcome & Introductions
Meningococcal Vaccines
- Introduction
- GSK Pentavalent Vaccine
- Updates
- MenQuadfi label change for infants
- Safety and immunogenicity
- Workgroup considerations
RSV Vaccines - Adults
- Introduction
- mRNA-1345 (Moderna) immunogenicity
- 18-59 at increased risk; 24-month re-vaccination
- Economic analyses
- Evidence to recommendation
- Clinical considerations
Chikungunya Vaccines
- Introduction
- Virus-like particle for travelers
- Adverse event surveillance
- Clinical guidance for pregnant and breastfeeding women
Public Comment
Votes
- Meningococcal Vaccines
- Meningococcal Vaccines VFC
- RSV Adult
- Chikungunya Vaccines
RSV Immunizations - Maternal/Pediatric
- Introduction
- Clesrovimab
- Clinical considerations
*The opinions expressed by the hosts and guests in this show are not necessarily the views of Children’s Health Defense.
Resources
